Urogen Pharma (NASDAQ:URGN) Stock Keeps “Buy” Rating at HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Monday, MarketBeat.com reports. They presently have a $75.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 119.23% from the stock’s current price.

URGN has been the topic of a number of other research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. TD Cowen raised their price target on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Guggenheim lifted their target price on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Oppenheimer boosted their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a research report on Thursday, July 16th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $52.38.

Urogen Pharma Trading Up 0.2%

Shares of Urogen Pharma stock opened at $34.21 on Monday. The firm has a market cap of $1.67 billion, a P/E ratio of -17.11 and a beta of 1.57. Urogen Pharma has a 12 month low of $16.50 and a 12 month high of $50.81. The stock’s fifty day moving average price is $42.91 and its 200-day moving average price is $35.51.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. Analysts forecast that Urogen Pharma will post -0.20 earnings per share for the current year.

Insider Transactions at Urogen Pharma

In other news, CFO Chris Degnan sold 2,202 shares of the company’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $36.69, for a total transaction of $80,791.38. Following the completion of the transaction, the chief financial officer directly owned 4,561 shares of the company’s stock, valued at $167,343.09. This represents a 32.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Jason Smith sold 1,519 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the transaction, the general counsel directly owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. The trade was a 2.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 65,269 shares of company stock valued at $3,037,646 in the last three months. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Persistent Asset Partners Ltd acquired a new position in shares of Urogen Pharma during the 2nd quarter worth about $66,000. Quantbot Technologies LP acquired a new position in shares of Urogen Pharma during the 2nd quarter worth about $78,000. Glenmede Trust Co. NA acquired a new position in shares of Urogen Pharma during the 1st quarter worth about $189,000. The Manufacturers Life Insurance Company acquired a new position in shares of Urogen Pharma during the 2nd quarter worth about $412,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Urogen Pharma during the 2nd quarter worth about $431,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.